15th Annual Midwest IDEAS Investor Conference
Logotype for Research Solutions Inc

Research Solutions (RSSS) 15th Annual Midwest IDEAS Investor Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Research Solutions Inc

15th Annual Midwest IDEAS Investor Conference summary

23 Jan, 2026

Company overview and strategy

  • Focuses on simplifying and accelerating scientific research using advanced AI and vertical SaaS solutions.

  • Serves both corporate (85% of revenue) and academic (10%) markets, with academic as the fastest-growing segment due to recent acquisitions.

  • Offers discovery tools, access to scientific articles, research management, and analytics, with unique AI-driven features like Smart Citations.

  • B2B and B2C models, with B2C growing via digital self-onboarding and B2B expanding through direct sales and upselling.

  • Maintains strong, long-term publisher relationships, enabling access to 250 million journal articles and unique full-text data mining rights for 60% of content.

Product differentiation and technology

  • Smart Citations provide unique article credibility metrics, unavailable elsewhere, leveraging exclusive data mining rights.

  • AI-powered Scite Assistant summarizes and analyzes articles in a copyright-compliant way, preserving publisher revenue.

  • Platform supports seamless research collaboration, article management, and compliance with copyright requirements.

  • Broadest access to STM content globally, with both full-text and abstract-based search depending on publisher agreements.

  • Recognized for workflow improvements and trusted by 1,400 organizations worldwide.

Market opportunity and growth

  • Total addressable market (TAM) estimated at $15 billion, with $4 billion in B2B and $11 billion in B2C, focused on research-intensive organizations.

  • SaaS software in research organizations projected to grow at 19% CAGR through 2030.

  • High customer retention: renewal rates in the mid- to high-90% range, net renewal rates after upsells between 100% and 110%.

  • Revenue diversified across pharma, biotech, medical device, and 60+ other verticals.

  • Business remains stable even during economic downturns, with research activity showing resilience.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more